Immunotherapy
LAG-3
PD-1
PET
TILs
Zirconium-89
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
31
10
2022
accepted:
18
02
2023
medline:
22
5
2023
pubmed:
2
3
2023
entrez:
1
3
2023
Statut:
ppublish
Résumé
Although lymphocyte activation gene-3 (LAG-3) directed therapies demonstrate promising clinical anti-cancer activity, only a subset of patients seems to benefit and predictive biomarkers are lacking. Here, we explored the potential use of the anti-LAG-3 antibody tracer [ Patients with head and neck (N = 2) or lung cancer (N = 4) were included in an imaging substudy of a phase 1 trial with BI 754091 (anti-PD-1) and BI 754111 (anti-LAG-3). After baseline tumor biopsy and [ Tracer uptake in tumors was clearly visible at the 4-mg mass dose (tumor-to-plasma ratio 1.63 [IQR 0.37-2.89]) and could be saturated by increasing mass doses (44 mg: 0.67 [IQR 0.50-0.85]; 604 mg: 0.56 [IQR 0.42-0.75]), demonstrating target specificity. Tumor uptake correlated to immune cell-derived RNA signatures. [ ClinicalTrials.gov , NCT03780725. Registered 19 December 2018.
Identifiants
pubmed: 36859619
doi: 10.1007/s00259-023-06164-w
pii: 10.1007/s00259-023-06164-w
pmc: PMC10199858
doi:
Substances chimiques
Radioisotopes
0
Zirconium
C6V6S92N3C
Banques de données
ClinicalTrials.gov
['NCT03780725']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2068-2080Informations de copyright
© 2023. The Author(s).
Références
Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol. Rev. 2017;276:80–96. https://doi.org/10.1111/imr.12519 .
doi: 10.1111/imr.12519
pubmed: 28258692
pmcid: 5338468
Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J. Exp. Med. 1990;171:1393–405. https://doi.org/10.1084/jem.171.5.1393 .
doi: 10.1084/jem.171.5.1393
pubmed: 1692078
Workman CJ, Wang Y, El Kasmi KC, Pardoll DM, Murray PJ, Drake CG, et al. LAG-3 regulates plasmacytoid dendritic cell homeostasis. J. Immunol. 2009;182:1885–91. https://doi.org/10.4049/jimmunol.0800185 .
doi: 10.4049/jimmunol.0800185
pubmed: 19201841
Lecocq Q, Keyaerts M, Devoogdt N, Breckpot K. The next-generation immune checkpoint LAG-3 and its therapeutic potential in oncology: third time’s a charm. Int. J. Mol. Sci. 2020;22:75. https://doi.org/10.3390/ijms22010075 .
doi: 10.3390/ijms22010075
pubmed: 33374804
pmcid: 7795594
Maruhashi T, Sugiura D, Okazaki IM, Okazaki T. LAG-3: from molecular functions to clinical applications. J. Immunother. Cancer. 2020;8:e001014. https://doi.org/10.1136/jitc-2020-001014 .
doi: 10.1136/jitc-2020-001014
pubmed: 32929051
pmcid: 7488795
Deng W-W, Mao L, Yu G-T, Bu L-L, Ma S-R, Liu B, et al. LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. Oncoimmunology. 2016;5:e1239005. https://doi.org/10.1080/2162402X.2016.1239005 .
doi: 10.1080/2162402X.2016.1239005
pubmed: 27999760
pmcid: 5139652
He Y, Yu H, Rozeboom L, Rivard CJ, Ellison K, Dziadziuszko R, et al. LAG-3 protein expression in non-small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes. J. Thorac. Oncol. 2017;12:814–23. https://doi.org/10.1016/j.jtho.2017.01.019 .
doi: 10.1016/j.jtho.2017.01.019
pubmed: 28132868
Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 2016;7:10501. https://doi.org/10.1038/ncomms10501 .
doi: 10.1038/ncomms10501
pubmed: 26883990
pmcid: 4757784
Lythgoe MP, Liu DSK, Annels NE, Krell J, Frampton AE. Gene of the month: lymphocyte-activation gene 3 (LAG-3). J. Clin. Pathol. 2021;74:543–7. https://doi.org/10.1136/jclinpath-2021-207517 .
doi: 10.1136/jclinpath-2021-207517
pubmed: 34183437
Gestermann N, Saugy D, Martignier C, Tille L, Fuertes Marraco SA, Zettl M, et al. LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures. Oncoimmunology. 2020;9:1736792. https://doi.org/10.1080/2162402X.2020.1736792 .
doi: 10.1080/2162402X.2020.1736792
pubmed: 32850194
pmcid: 7422827
Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, et al. Targeting LAG-3 and PD-1 to enhance t cell activation by antigen-presenting cells. Front. Immunol. 2018;9:385. https://doi.org/10.3389/fimmu.2018.00385 .
doi: 10.3389/fimmu.2018.00385
pubmed: 29535740
pmcid: 5835137
Zhai W, Zhou X, Wang H, Li W, Chen G, Sui X, et al. A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8(+) T cell responses. Acta Pharm Sin B. 2020;10:1047–60. https://doi.org/10.1016/j.apsb.2020.01.005 .
doi: 10.1016/j.apsb.2020.01.005
pubmed: 32642411
pmcid: 7332792
Goding SR, Wilson KA, Xie Y, Harris KM, Baxi A, Akpinarli A, et al. Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma. J. Immunol. 2013;190:4899–909. https://doi.org/10.4049/jimmunol.1300271 .
doi: 10.4049/jimmunol.1300271
pubmed: 23536636
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutierrez E, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 2022;386:24–34. https://doi.org/10.1056/NEJMoa2109970 .
doi: 10.1056/NEJMoa2109970
pubmed: 34986285
pmcid: 9844513
van Dongen G, Beaino W, Windhorst AD, Zwezerijnen GJC, Oprea-Lager DE, Hendrikse NH, et al. The role of (89)Zr-Immuno-PET in navigating and derisking the development of biopharmaceuticals. J. Nucl. Med. 2021;62:438–45. https://doi.org/10.2967/jnumed.119.239558 .
doi: 10.2967/jnumed.119.239558
pubmed: 33277395
Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen G, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat. Commun. 2018;9:4664. https://doi.org/10.1038/s41467-018-07131-y .
doi: 10.1038/s41467-018-07131-y
pubmed: 30405135
pmcid: 6220188
Niemeijer AN, Oprea-Lager DE, Huisman MC, Hoekstra OS, Boellaard R, de Wit-van der Veen BJ, et al. Study of (89)Zr-Pembrolizumab PET/CT in patients with advanced-stage non-small cell lung cancer. J. Nucl. Med. 2022;63:362–7. https://doi.org/10.2967/jnumed.121.261926 .
doi: 10.2967/jnumed.121.261926
pubmed: 34272316
Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat. Med. 2018;24:1852–8. https://doi.org/10.1038/s41591-018-0255-8 .
doi: 10.1038/s41591-018-0255-8
pubmed: 30478423
Zhang Q, Salzler R, Dore A, Yang J, Ma D, Olson WC, et al. Multiplex immuno-liquid chromatography-mass spectrometry-parallel reaction monitoring (LC-MS-PRM) quantitation of CD8A, CD4, LAG3, PD1, PD-L1, and PD-L2 in frozen human tissues. J. Proteome Res. 2018;17:3932–40. https://doi.org/10.1021/acs.jproteome.8b00605 .
doi: 10.1021/acs.jproteome.8b00605
pubmed: 30277784
Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419. https://doi.org/10.1126/science.1260419 .
doi: 10.1126/science.1260419
pubmed: 25613900
Woo SR, Li N, Bruno TC, Forbes K, Brown S, Workman C, et al. Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4. Eur. J. Immunol. 2010;40:1768–77. https://doi.org/10.1002/eji.200939874 .
doi: 10.1002/eji.200939874
pubmed: 20391435
pmcid: 2987677
Bae J, Lee SJ, Park CG, Lee YS, Chun T. Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling. J. Immunol. 2014;193:3101–12. https://doi.org/10.4049/jimmunol.1401025 .
doi: 10.4049/jimmunol.1401025
pubmed: 25108024
der Houven M-v, van Oordt CW, McGeoch A, Bergstrom M, McSherry I, Smith DA, Cleveland M, et al. Immuno-PET imaging to assess target engagement: experience from (89)Zr-Anti-HER3 mAb (GSK2849330) in patients with solid tumors. J. Nucl. Med. 2019;60:902–9. https://doi.org/10.2967/jnumed.118.214726 .
doi: 10.2967/jnumed.118.214726
Viala M, Vinches M, Alexandre M, Mollevi C, Durigova A, Hayaoui N, et al. Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection. Br. J. Cancer. 2018;118:679–97. https://doi.org/10.1038/bjc.2017.473 .
doi: 10.1038/bjc.2017.473
pubmed: 29438365
pmcid: 5846071
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur. J. Nucl. Med. Mol. Imaging. 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x .
doi: 10.1007/s00259-014-2961-x
pubmed: 25452219
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026 .
doi: 10.1016/j.ejca.2008.10.026
pubmed: 19097774
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143–e52. https://doi.org/10.1016/S1470-2045(17)30074-8 .
doi: 10.1016/S1470-2045(17)30074-8
pubmed: 28271869
pmcid: 5648544
World Medical A. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191–4. https://doi.org/10.1001/jama.2013.281053 .
doi: 10.1001/jama.2013.281053
European Medicines Agency. ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals. 2009. Available online at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002720.pdf . Accessed 23 Feb 2023.
Greuter HN, van Ophemert PL, Luurtsema G, Franssen EJ, Boellaard R, Lammertsma AA. Validation of a multiwell gamma-counter for measuring high-pressure liquid chromatography metabolite profiles. J. Nucl. Med. Technol. 2004;32:28–32.
pubmed: 14990672
Lammertsma AA, Hoekstra CJ, Giaccone G, Hoekstra OS. How should we analyse FDG PET studies for monitoring tumour response? Eur. J. Nucl. Med. Mol. Imaging. 2006;33(Suppl1):16–21. https://doi.org/10.1007/s00259-006-0131-5 .
doi: 10.1007/s00259-006-0131-5
pubmed: 16763817
Jauw YWS, O’Donoghue JA, Zijlstra JM, Hoekstra OS, der Houven M-v, van Oordt CW, Morschhauser F, et al. (89)Zr-Immuno-PET: toward a noninvasive clinical tool to measure target engagement of therapeutic antibodies in vivo. J. Nucl. Med. 2019;60:1825–32. https://doi.org/10.2967/jnumed.118.224568 .
doi: 10.2967/jnumed.118.224568
pubmed: 31147401
Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat. Protoc. 2010;5:739–43. https://doi.org/10.1038/nprot.2010.13 .
doi: 10.1038/nprot.2010.13
pubmed: 20360768
Boellaard R. Quantitative oncology molecular analysis suite: ACCURATE [abstract]. J. Nucl. Med. 2018;59(suppl.1):1753.
Jauw YWS, Bensch F, Brouwers AH, Hoekstra OS, Zijlstra JM, Pieplenbosch S, et al. Interobserver reproducibility of tumor uptake quantification with (89)Zr-immuno-PET: a multicenter analysis. Eur. J. Nucl. Med. Mol. Imaging. 2019;46:1840–9. https://doi.org/10.1007/s00259-019-04377-6 .
doi: 10.1007/s00259-019-04377-6
pubmed: 31209514
pmcid: 6647131
Makris NE, Boellaard R, Visser EP, de Jong JR, Vanderlinden B, Wierts R, et al. Multicenter harmonization of 89Zr PET/CT performance. J. Nucl. Med. 2014;55:264–7. https://doi.org/10.2967/jnumed.113.130112 .
doi: 10.2967/jnumed.113.130112
pubmed: 24357686
Andrews S. FastQC: a quality control tool for high throughput sequence data. 2010. Available online at: http://www.bioinformatics.babraham.ac.uk/projects/fastqc/ . Accessed 23 Feb 2023.
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21. https://doi.org/10.1093/bioinformatics/bts635 .
doi: 10.1093/bioinformatics/bts635
pubmed: 23104886
Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011;12:323. https://doi.org/10.1186/1471-2105-12-323 .
doi: 10.1186/1471-2105-12-323
pubmed: 21816040
pmcid: 3163565
Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. https://doi.org/10.1186/s13059-014-0550-8 .
doi: 10.1186/s13059-014-0550-8
pubmed: 25516281
pmcid: 4302049
Sturm G, Finotello F, List M. Immunedeconv: an R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data. Methods Mol. Biol. 2020;2120:223–32. https://doi.org/10.1007/978-1-0716-0327-7_16 .
doi: 10.1007/978-1-0716-0327-7_16
pubmed: 32124323
Wickham H. ggplot2: elegant graphics for data analysis. 2016. Available online at: https://ggplot2.tidyverse.org . Accessed 23 Feb 2023.
Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417–25. https://doi.org/10.1016/j.cels.2015.12.004 .
doi: 10.1016/j.cels.2015.12.004
pubmed: 26771021
pmcid: 4707969
Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577:561–5. https://doi.org/10.1038/s41586-019-1914-8 .
doi: 10.1038/s41586-019-1914-8
pubmed: 31942071
Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7. https://doi.org/10.1186/1471-2105-14-7 .
doi: 10.1186/1471-2105-14-7
pubmed: 23323831
pmcid: 3618321
Li Q, Liu X, Wang D, Wang Y, Lu H, Wen S, et al. Prognostic value of tertiary lymphoid structure and tumour infiltrating lymphocytes in oral squamous cell carcinoma. Int. J. Oral Sci. 2020;12:24. https://doi.org/10.1038/s41368-020-00092-3 .
doi: 10.1038/s41368-020-00092-3
pubmed: 32934197
pmcid: 7493903
Silina K, Soltermann A, Attar FM, Casanova R, Uckeley ZM, Thut H, et al. Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res. 2018;78:1308–20. https://doi.org/10.1158/0008-5472.CAN-17-1987 .
doi: 10.1158/0008-5472.CAN-17-1987
pubmed: 29279354
Lecocq Q, Awad RM, De Vlaeminck Y, de Mey W, Ertveldt T, Goyvaerts C, et al. Single-domain antibody nuclear imaging allows noninvasive quantification of LAG-3 expression by tumor-infiltrating leukocytes and predicts response of immune checkpoint blockade. J. Nucl. Med. 2021;62:1638–44. https://doi.org/10.2967/jnumed.120.258871 .
doi: 10.2967/jnumed.120.258871
pubmed: 33712537
pmcid: 8612328
Lecocq Q, Zeven K, De Vlaeminck Y, Martens S, Massa S, Goyvaerts C, et al. Noninvasive imaging of the immune checkpoint LAG-3 using nanobodies, from development to pre-clinical use. Biomolecules. 2019;9:548. https://doi.org/10.3390/biom9100548 .
doi: 10.3390/biom9100548
pubmed: 31569553
pmcid: 6843898
Chen B, Tang Y, Rao W, Zhu Z, Xiang S, Xiao L, et al. A novel PET imaging probe of LAG-3 expression on tumor-infiltrating lymphocytes: in preclinical use. J. Nucl. Med. 2022;63:2455.
Katal S, Eibschutz LS, Saboury B, Gholamrezanezhad A, Alavi A. Advantages and applications of total-body PET scanning. Diagnostics (Basel). 2022;12:246. https://doi.org/10.3390/diagnostics12020426 .
doi: 10.3390/diagnostics12020426